
News|Videos|November 11, 2026
Executive Conversations: When Should Trade Teams Join Launch Planning?
In Episode 1, Part 2, Jon Hamrick, Bob Cochran and Rena Goins explain why trade belongs in commercial planning at least a year before launch.
Advertisement
Advertisement
The first episode of Executive Conversations: The Future of Pharmaceutical Commercialization, presented by Pharmaceutical Commerce, continues with a look at when trade teams should join commercial planning and which prelaunch decisions benefit most from their input. Host Jon Hamrick, partner at Curatio Advisors, is joined by Rena Goins, executive director, global trade at Regeneron Pharmaceuticals, and Bob Cochran, former senior director of trade relations at Incyte, who recently joined Curatio Advisors as a senior advisor.
Related to this article

In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.

Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.

Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.

CVS Health’s proposed separation of its retail pharmacy business from insurance and pharmacy benefit management raises a fundamental question: Will changing ownership improve pharmaceutical distribution, competition and patient access, or simply redistribute market power?

Joint clinical assessment, shifting HTA demands and pricing pressure are making launch the start of continuous evidence generation.

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.

EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence planning must start earlier.
Advertisement
Advertisement

